Trabectedin and
eribulin are two agents that have been recently approved for the treatment of specific
soft tissue sarcoma subtypes. They have proved to be a much-needed line of additional treatment for patients with these rare
tumors, but their activity remains admittedly modest in most cases. Further exploitation of these novel agents is likely to require a more granular understanding of the salient mechanisms of action. For example, if as some studies suggest,
eribulin derives its benefit from restructuring of
tumor vasculature to improve efficacy of subsequent lines of
therapy, then patients may benefit from its use earlier in the treatment pathway. The sequencing of
trabectedin with other agents is also worth examining. In a disease like
myxoid liposarcoma, consideration should be given to using
trabectedin before other salvage regimens like
gemcitabine and
docetaxel, given its tolerability and excellent efficacy against this
sarcoma subtype. Also, to be further investigated is the use of
trabectedin in
sarcoma subtypes which were excluded from the phase III study, but in which activity has been documented in earlier trials and subsequent reports. Combinations of
trabectedin with other agents, particularly
doxorubicin, have been explored, but the data to date do not support the routine use of these regimens.